What Happens If You Only Get One Shingles Shot?

One dose of Shingrix, the current shingles vaccine, provides real but incomplete protection. Real-world studies put its effectiveness against shingles at roughly 57 to 64 percent after a single shot, compared to 70 to 76 percent after the full two-dose series, and that partial shield tends to weaken faster than what two doses provide. About one in four people who start the series never finish it, making this one of the most common vaccine-completion gaps in adult medicine.

How Much Protection a Single Dose Actually Provides

Shingrix was designed and tested as a two-dose vaccine, with the second shot given two to six months after the first. But because so many people end up with only one dose, researchers have looked at what that first shot accomplishes on its own. Observational data from real-world populations show a single dose reduces the risk of developing shingles by somewhere around 57 to 64 percent, depending on the study. The complete two-dose series pushes that figure up to about 70 to 76 percent. So one dose does more than nothing, but it leaves a meaningful gap in protection.¹

The more concerning finding is how quickly that single-dose protection fades. Studies note that effectiveness after one dose drops significantly after the first year, whereas two doses hold up considerably longer. This matters because shingles risk increases with age, meaning the people most likely to need the vaccine are also the ones who need durable protection over many years, not just a few months of partial coverage.

Why Protection After One Dose Fades Faster

The immune system’s response to a vaccine is a bit like building a skill through repetition. The first dose introduces the immune system to the target, in this case a protein from the varicella-zoster virus paired with a strong immune-stimulating ingredient called an adjuvant. Your body produces antibodies and memory cells, but that initial response needs reinforcement. The second dose acts as a booster that pushes the immune response higher and, more importantly, makes it last.

Research on booster doses given years after primary vaccination shows a pattern that helps explain this. When people who had already completed the two-dose series received an additional dose five to six years later, their antibody levels surged to very high peaks within a month but then settled back down over the following year, eventually stabilizing at a level well above where they started. Whether they got one additional dose or two made little difference to those long-term levels.²

What this tells us is that the immune system has a ceiling for how much antibody it can sustain against a given target, and it takes the right sequence of exposures to build the sturdiest possible defense. A single dose creates a peak that looks impressive in the short term but doesn’t build the same lasting memory. The second dose locks that memory in place, which is why the two-dose effectiveness holds steady for years while the single-dose protection erodes.

Does One Dose Still Protect Against the Worst Complication?

The most feared consequence of shingles isn’t the rash itself but postherpetic neuralgia, or PHN, a burning nerve pain that can persist for months or even years after the rash heals. Before Shingrix, the United States and other countries used a different, older shingles vaccine called Zostavax, which was a single-dose live vaccine. Studies of Zostavax offer some insight into whether partial vaccination helps against PHN, because every vaccinated person in those studies received only one dose by design.

In one large study of people who developed shingles despite having received Zostavax, vaccinated women had roughly 60 percent lower risk of developing PHN compared to unvaccinated women. In men, however, the protective effect against PHN was not statistically meaningful.³

This result is specific to the older vaccine, not to Shingrix, and the sex difference in PHN protection was never fully explained. But it illustrates an important principle: even incomplete vaccination can sometimes reduce the severity of a breakthrough infection, not just prevent it. If you do develop shingles after one dose of Shingrix, the immune priming from that first shot may help your body fight the virus more quickly, potentially making the episode shorter or less severe. The evidence for this with Shingrix specifically is still being built, but the biological logic is sound.

How Many People End Up With Only One Dose

The gap between starting and finishing the Shingrix series is wider than most people assume. Among Medicare beneficiaries who received their first dose in the first half of 2018, about one in four had not received the second dose within six months.⁴ A broader analysis across U.S. adults found that about 70 percent completed the series within six months and roughly 80 percent within a year, meaning one in five people were still unfinished after twelve months.⁵

These numbers represent millions of adults walking around with partial protection and potentially no awareness that their shield is weaker than they think. Many people remember getting “the shingles vaccine” and consider the matter settled, not realizing the second dose was never completed. Unlike some vaccines where a single dose is simply a smaller version of the same protection, with Shingrix the second dose is doing qualitatively different immunological work, and skipping it isn’t like getting 90 percent of the benefit.

Who Tends to Miss the Second Shot

Completion rates vary significantly by income, race, and age. Among Medicare beneficiaries, only about 64 percent of those with lower incomes completed the series within six months, compared to 77 percent of higher-income beneficiaries. White beneficiaries had the highest completion rate at about 76 percent, while Hispanic, Black, and American Indian/Alaska Native beneficiaries completed at rates between 58 and 61 percent. Asian/Pacific Islander beneficiaries fell in between at around 69 percent.⁴

Age also plays a role, but not in the direction you might expect. Beneficiaries under 65 had a lower completion rate (about 66 percent within six months) than those aged 65 to 84, who completed at 75 to 76 percent. Adults 85 and older dipped slightly to 71 percent but still outpaced the youngest eligible group. The reasons are likely a tangle of logistics, cost exposure, and health system engagement. Younger adults eligible through immunocompromising conditions may face different insurance structures. Lower-income and minority populations may encounter more barriers related to pharmacy access, out-of-pocket costs, or not receiving follow-up reminders.

These disparities matter because the groups least likely to complete the series overlap with groups that face higher rates of shingles complications. Incomplete vaccination in these populations compounds existing health inequities rather than narrowing them.

What If You’re Late Getting the Second Dose

One of the most common practical questions people have is whether they’ve “missed the window” for the second dose. The recommended interval is two to six months after the first shot. If you’re past that window, the good news is straightforward: you should still get the second dose. You don’t need to restart the series. The CDC has consistently advised that a delayed second dose should be given as soon as possible, regardless of how much time has passed since the first.

There is no evidence that a late second dose is harmful or that it produces an inferior immune response compared to one given on schedule. Your immune system retains memory of the first dose for a long time, and the second dose can still act on that foundation even if months or a couple of years have passed. The concern is not that a late second dose won’t work, but that every month you spend with only one dose is a month of suboptimal protection. The virus that causes shingles is already dormant in your body from a prior chickenpox infection, and it can reactivate without warning.

If you’re unsure whether you completed the series, your pharmacy may have records, or you can check through your state’s immunization registry. Some people genuinely don’t remember, and in that case it’s generally considered safe to receive what would effectively be a third dose of Shingrix rather than remain potentially unprotected.

Pharmacy Reminders Make a Real Difference

The fact that so many people fall off the two-dose schedule has prompted health systems to test simple interventions to close the gap. One large study involving over 120,000 adults tested the effect of pharmacy-based reminders, including text messages to patients and prompts to pharmacists during patient visits. The results were striking: completion rates rose to about 85 to 88 percent when these nudges were in place, significantly higher than baseline. Patients who received text reminders completed the series about nine days sooner than those who received only in-pharmacy prompts from the pharmacist.⁶

Nine days faster might not sound like much, but in the context of vaccine completion, speed matters because every additional day of delay increases the chance the person never comes back at all. The takeaway for you is practical: if you’ve had your first dose and haven’t scheduled the second, set a reminder in your phone or ask the pharmacy to text you. The barrier for most people isn’t reluctance or fear but simple forgetfulness and the friction of scheduling a second appointment.

When the Immune System Is Already Compromised

People with weakened immune systems, whether from medical conditions, organ transplants, or immunosuppressive medications, face a higher risk of shingles and tend to have more severe cases. Shingrix is recommended for these patients specifically because it is not a live vaccine (unlike the older Zostavax, which could not safely be given to immunocompromised people). But incomplete vaccination is especially consequential in this group because their immune systems are less capable of building strong responses even under ideal conditions.

A small study of immunocompromised pediatric patients who had never been exposed to the varicella-zoster virus illustrated this vividly. Among ten patients who received the vaccine, nine developed detectable antibodies. The one patient who remained without any measurable immune response was the one who had received only a single dose.⁷

This is a tiny study, so it’s not the basis for sweeping conclusions. But it vividly demonstrates the risk: in someone whose immune system is already struggling, a single dose may not be enough to generate any meaningful protection at all. For immunocompromised individuals, completing the two-dose series isn’t just about getting better protection. It may be the difference between getting some protection and getting essentially none.

The Cost of Incomplete Vaccination at a Population Level

When researchers model the public health impact of shingles vaccination, they have to account for the reality that not everyone finishes the series. A Canadian cost-effectiveness analysis used real-world data showing that only about 65 percent of people who got a first dose went on to complete the series. That figure was built into their projections of how many shingles cases, hospitalizations, and cases of postherpetic neuralgia the vaccination program would prevent.⁸

The implication is that the real-world effectiveness of any shingles vaccination program is dragged down not just by people who skip vaccination entirely but by the substantial chunk who start but don’t finish. From a public health perspective, improving series completion is one of the most cost-effective things health systems can do, because the infrastructure and expense of delivering the first dose are already spent. Getting the second dose into people’s arms is a much cheaper lift than recruiting new patients into the program.

How Shingrix Compares to Other Multi-Dose Vaccines

The completion problem isn’t unique to Shingrix. Any vaccine that requires more than one visit faces the same challenge of getting people back through the door. The HPV vaccine originally required three doses, and studies found that some people who received fewer than three doses still showed meaningful protection against targeted infections, though with caveats about limited follow-up and sample sizes.⁹ Those findings eventually contributed to changes in the HPV vaccine schedule for younger recipients.

With Shingrix, the story is less forgiving. The partial protection from one dose is meaningful but wanes faster, and the target population of older adults faces a rising and relentless risk of shingles reactivation. For HPV, the immune system of a teenager responds robustly even to a single dose, and the infections being prevented are years or decades away. For shingles, the immune systems in question are aging, and the virus is already sitting in nerve cells waiting for an opportunity. The margin for partial protection is thinner, and the consequences of breakthrough disease are more immediate.

The Older Shingles Vaccine Was a One-Dose Shot

If you were vaccinated before late 2017 in the United States or before 2023 in England, you likely received Zostavax, the older live attenuated vaccine that required only a single dose. Zostavax was less effective than Shingrix overall, and its protection waned more quickly, especially in adults over 70. England’s national program, for example, used Zostavax from its launch in 2013 until replacing it with Shingrix in September 2023.¹

If you received Zostavax years ago, the CDC recommends getting the full two-dose Shingrix series regardless. Zostavax protection is considered to have faded substantially after five to eight years, and Shingrix works through a different mechanism, so there’s no redundancy. This is a distinct situation from having had one dose of Shingrix and needing the second. People who had Zostavax need a full two-dose Shingrix course to get current protection.

The transition between vaccines has created some confusion, with patients sometimes unsure which vaccine they received or whether Zostavax “counts” toward the Shingrix series. It does not. The two vaccines are immunologically different products, and receiving Zostavax in the past does not substitute for either dose of Shingrix.

Side Effects and Whether They Deter the Second Dose

Shingrix is known for producing noticeable side effects, more so than many adult vaccines. Sore arms, fatigue, muscle aches, and sometimes fever are common in the days following injection, and some people find the experience unpleasant enough to hesitate about returning for the second dose. Anecdotally, many providers report that patients who had a strong reaction to the first dose express reluctance about the second.

The reality is that the side effects of the second dose are generally similar to the first. Some people report a slightly stronger reaction the second time, others a milder one, and many notice no difference. These reactions are signs of a vigorous immune response, which is exactly what the vaccine is designed to provoke. They typically resolve within two to three days. Compared to the pain and disruption of a shingles outbreak, which can last weeks and sometimes leads to months of nerve pain, a couple of days of feeling run down is a trade most people would accept gladly if they understood the comparison clearly.

If you had a rough reaction to the first dose and have been putting off the second, it may help to schedule it for a day when you can take it easy the following day. Over-the-counter pain relievers can also help manage symptoms. The short-term discomfort is a poor reason to leave yourself with fading partial protection against a virus that becomes more likely to strike with every passing year.